CAR--话题@MedSci

#CAR-#

459篇内容 | 2253人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781468, encodeId=50791e8146857, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cell Metabolism：陈斯迪团队利用CRISPR筛选，发现增强CAR-T效果新手段, objectType=article, longId=300540, objectId=a882300540f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a882300540f9, replyNumber=0, likeNumber=65, createdTime=2022-09-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a882300540f9, moduleTitle=Cell Metabolism：陈斯迪团队利用CRISPR筛选，发现增强CAR-T效果新手段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a882300540f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781461, encodeId=752e1e8146139, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持, objectType=article, longId=295110, objectId=31a329511012, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a329511012, replyNumber=0, likeNumber=54, createdTime=2022-07-12, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a329511012, moduleTitle=BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31a329511012)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781463, encodeId=2d6c1e8146347, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Sci Transl Med：摘去肿瘤细胞的“糖衣”，CAR-T即成为“炮弹”！, objectType=article, longId=295419, objectId=ae3c295419f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae3c295419f8, replyNumber=0, likeNumber=74, createdTime=2022-10-31, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae3c295419f8, moduleTitle=Sci Transl Med：摘去肿瘤细胞的“糖衣”，CAR-T即成为“炮弹”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae3c295419f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781444, encodeId=dcb21e8144400, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CDE发布征求CAR-T指导原则意见, objectType=article, longId=217337, objectId=cb4e21e337de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb4e21e337de, replyNumber=0, likeNumber=45, createdTime=2022-05-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb4e21e337de, moduleTitle=CDE发布征求CAR-T指导原则意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb4e21e337de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781454, encodeId=01b21e81454ef, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=同济医院完成首次国产CAR-T治疗！真是120万一针？专家回应价格情况, objectType=article, longId=221363, objectId=fffc221363d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fffc221363d6, replyNumber=0, likeNumber=59, createdTime=2022-11-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fffc221363d6, moduleTitle=同济医院完成首次国产CAR-T治疗！真是120万一针？专家回应价格情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fffc221363d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781428, encodeId=ed381e814286a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, objectType=article, longId=210740, objectId=e5eb210e403b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5eb210e403b, replyNumber=0, likeNumber=79, createdTime=2022-03-01, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5eb210e403b, moduleTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5eb210e403b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781438, encodeId=d1ad1e8143889, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature Medicine：CD19-CD22双靶点CAR-T临床试验结果发布, objectType=article, longId=215111, objectId=7ebf2151117e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ebf2151117e, replyNumber=0, likeNumber=76, createdTime=2022-05-31, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ebf2151117e, moduleTitle=Nature Medicine：CD19-CD22双靶点CAR-T临床试验结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ebf2151117e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781422, encodeId=2d731e81422c3, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, objectType=article, longId=209107, objectId=d5a420910e55, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5a420910e55, replyNumber=0, likeNumber=55, createdTime=2022-02-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5a420910e55, moduleTitle=BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5a420910e55)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781456, encodeId=64221e814568b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, objectType=article, longId=292171, objectId=e81a2921e11f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e81a2921e11f, replyNumber=0, likeNumber=46, createdTime=2022-05-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e81a2921e11f, moduleTitle=Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e81a2921e11f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781421, encodeId=0c7f1e814215e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=里程碑！CAR-M疗法首次用于人体研究, objectType=article, longId=208887, objectId=6a3720888ea8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a3720888ea8, replyNumber=0, likeNumber=58, createdTime=2022-01-31, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a3720888ea8, moduleTitle=里程碑！CAR-M疗法首次用于人体研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a3720888ea8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781436, encodeId=36601e814366f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, objectType=article, longId=214948, objectId=920821494873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=920821494873, replyNumber=0, likeNumber=54, createdTime=2022-06-25, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=920821494873, moduleTitle=Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=920821494873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781415, encodeId=11f41e8141590, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Commun：CAR-T细胞通过介导免疫抑制性肿瘤相关巨噬细胞的耗竭增强免疫疗法的疗效, objectType=article, longId=207192, objectId=998320e19299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=998320e19299, replyNumber=0, likeNumber=75, createdTime=2021-08-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=998320e19299, moduleTitle=Nat Commun：CAR-T细胞通过介导免疫抑制性肿瘤相关巨噬细胞的耗竭增强免疫疗法的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=998320e19299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781424, encodeId=e0291e814241a, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=4大上市CAR-T药企2020成绩单公布, objectType=article, longId=209474, objectId=b6592094e441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6592094e441, replyNumber=0, likeNumber=68, createdTime=2021-09-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6592094e441, moduleTitle=4大上市CAR-T药企2020成绩单公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6592094e441)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781414, encodeId=5ee81e814147c, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature子刊：CAR-T治疗全球专利格局深度分析, objectType=article, longId=207120, objectId=5b7c20e120d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b7c20e120d4, replyNumber=0, likeNumber=43, createdTime=2021-02-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b7c20e120d4, moduleTitle=Nature子刊：CAR-T治疗全球专利格局深度分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b7c20e120d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781439, encodeId=abec1e8143979, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮, objectType=article, longId=215829, objectId=75e621582978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75e621582978, replyNumber=0, likeNumber=73, createdTime=2021-10-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75e621582978, moduleTitle=NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75e621582978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781455, encodeId=53f71e81455c6, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cell：CAR-T之父全新Cell论文：发现新靶点，助力CAR-T攻克实体瘤, objectType=article, longId=221647, objectId=b4c322164e05, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4c322164e05, replyNumber=0, likeNumber=73, createdTime=2022-07-05, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4c322164e05, moduleTitle=Cell：CAR-T之父全新Cell论文：发现新靶点，助力CAR-T攻克实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4c322164e05)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781451, encodeId=62451e81451ed, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature：新型CAR-T疗法，有望靶向治疗各种类型癌症, objectType=article, longId=220215, objectId=173a2202152e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=173a2202152e, replyNumber=0, likeNumber=56, createdTime=2021-12-07, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=173a2202152e, moduleTitle=Nature：新型CAR-T疗法，有望靶向治疗各种类型癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=173a2202152e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781416, encodeId=573c1e81416c7, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=NEJM：淋巴瘤患者新希望！CAR-T治疗七成患者5年后仍处于缓解期, objectType=article, longId=207386, objectId=604120e3866e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=604120e3866e, replyNumber=0, likeNumber=61, createdTime=2021-04-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=604120e3866e, moduleTitle=NEJM：淋巴瘤患者新希望！CAR-T治疗七成患者5年后仍处于缓解期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=604120e3866e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781435, encodeId=732d1e814352b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nat Med：局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究, objectType=article, longId=214242, objectId=a2d6214242c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d6214242c7, replyNumber=0, likeNumber=135, createdTime=2022-03-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d6214242c7, moduleTitle=Nat Med：局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d6214242c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781440, encodeId=13241e8144022, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Frontiers in Oncology：双管齐下：化疗减瘤+CAR-T治疗，提高高肿瘤负荷淋巴瘤患者缓解率和总生存率, objectType=article, longId=215868, objectId=a06721586815, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a06721586815, replyNumber=0, likeNumber=66, createdTime=2021-11-26, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a06721586815, moduleTitle=Frontiers in Oncology：双管齐下：化疗减瘤+CAR-T治疗，提高高肿瘤负荷淋巴瘤患者缓解率和总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a06721586815)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Cell Metabolism：陈斯迪团队利用CRISPR筛选，发现增强CAR-T效果新手段

2022-09-07

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

BMS获得欧盟委员会对CAR-T疗法Breyanzi的支持

2022-07-12

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Sci Transl Med：摘去肿瘤细胞的“糖衣”，CAR-T即成为“炮弹”！

2022-10-31

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CDE发布征求CAR-T指导原则意见

2022-05-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

同济医院完成首次国产CAR-T治疗！真是120万一针？专家回应价格情况

2022-11-13

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL

2022-03-01

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature Medicine：CD19-CD22双靶点CAR-T临床试验结果发布

2022-05-31

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

BMS的CAR-T细胞疗法治疗多发性骨髓瘤，已获得FDA批准

2022-02-20

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：p32 CAR-T细胞：胶质母细胞瘤的潜在治疗选择

2022-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

里程碑！CAR-M疗法首次用于人体研究

2022-01-31

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Med：靶向CD19和CD22的双特异性CAR-T疗法可治疗复发性/难治性B细胞恶性肿瘤

2022-06-25

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Commun：CAR-T细胞通过介导免疫抑制性肿瘤相关巨噬细胞的耗竭增强免疫疗法的疗效

2021-08-28

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

4大上市CAR-T药企2020成绩单公布

2021-09-10

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature子刊：CAR-T治疗全球专利格局深度分析

2021-02-26

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

NEJM：CAR-T细胞疗法首次成功治疗红斑狼疮

2021-10-30

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Cell：CAR-T之父全新Cell论文：发现新靶点，助力CAR-T攻克实体瘤

2022-07-05

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature：新型CAR-T疗法，有望靶向治疗各种类型癌症

2021-12-07

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

NEJM：淋巴瘤患者新希望！CAR-T治疗七成患者5年后仍处于缓解期

2021-04-11

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nat Med：局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究

2022-03-10

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Frontiers in Oncology：双管齐下：化疗减瘤+CAR-T治疗，提高高肿瘤负荷淋巴瘤患者缓解率和总生存率

2021-11-26

科室
- - 订阅+
  - 更多科室
工具
服务